Company Information

  

Address: 8000 MARINA BOULEVARD
SUITE 300 
City: BRISBANE 
State: CA 
Zip Code: 94005-1884 
Telephone: (650) 614-5220 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. It is estimated that over 30 million people in the United States and Europe have a food allergy, with peanut allergy being the most prevalent and most commonly associated with severe outcomes and life-threatening events. There are currently no approved medical therapies to cure food allergies or prevent their symptoms. Patients with food allergies are typically counseled to practice strict dietary avoidance. When accidental exposure to food allergens invokes a serious allergic reaction, rescue therapies, such as antihistamines or injectable epinephrine, are the only recourse available.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
09/2017-2.35NAN/E
06/2017-2.24NAN/E
03/2017-2.04NAN/E
12/2016-1.89NAN/E
09/20162.28NA6.58
06/20163.52NA3.07
03/20162.32NA5.84
12/20151.88NA9.81

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.19Total Liab/Total Assets0.04
Net Inc/Total Assets-0.27Total Liab/Inv Cap0.04
Net Inc/Inv Cap-0.28Total Liab/Comm Equity0.03
Pretax Inc/Net SalesNAInterest Coverage RatioNA
Net Inc/Net SalesNACurr Debt/EquityNA
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio21.98
Inventory TurnoverNACurrent Ratio21.98
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  9/30/2017 6/30/2017 3/31/2017 12/31/2016
Total Revenues(Net Sales) NA NA NA NA
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 11.23 10.81 8.92 8.34
Operating Income -32.29 -33.00 -26.34 -25.30
Interest Exp NA NA NA NA
Pretax Income -31.79 -32.50 -25.87 -25.08
Other Income 0.50 0.51 0.47 0.23
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -31.79 -32.50 -25.87 -25.08

Balance Sheet (Millions)

Assets 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Cash & Short Term Investments 212.03 237.33 246.25 248.93
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 218.09 242.61 248.87 251.68
Net Property, Plant & Equipment 14.94 13.14 11.15 10.39
Total Assets 233.67 256.35 276.29 298.79
Liabilities        
Accounts Payable 21.15 17.93 10.12 11.35
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 21.19 18.04 10.22 11.45
Long-Term Debt NA NA NA NA
Total Liabilities 23.08 19.56 11.57 12.82
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA 0.00
Common Stock 0.01 0.01 0.01 0.01
Retained Earnings -224.32 -192.52 -160.03 -134.16
Treasury Stock NA NA NA NA
Total Stockholders' Equity 210.59 236.79 264.72 285.97
Total Liabilities and Stockholders' Equity 233.67 256.35 276.29 298.79

Cash Flow Summary (Millions)

Categories 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Net Cash Provided by Operating Activities -24.33 -20.25 -23.10 -22.61
Net Cash Provided by Investing Activities 12.25 25.60 -23.31 -77.33
Net Cash Provided by Financing Activities 1.45 0.39 1.12 147.04

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.00-4.82--
12/20140.00-11.12--
12/20150.00-35.821.88
12/20160.00-80.82-1.89
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/1710937,36073.45




Report Date : 12/4/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.